Aperio Group LLC boosted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 12.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,287 shares of the company’s stock after buying an additional 5,488 shares during the period. Aperio Group LLC’s holdings in BioMarin Pharmaceutical were worth $4,653,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. raised its position in shares of BioMarin Pharmaceutical by 18.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 247,100 shares of the company’s stock worth $19,225,000 after buying an additional 38,628 shares in the last quarter. ING Groep NV bought a new position in shares of BioMarin Pharmaceutical during the second quarter worth approximately $57,357,000. William Blair Investment Management LLC raised its position in shares of BioMarin Pharmaceutical by 27.3% in the second quarter. William Blair Investment Management LLC now owns 1,254,176 shares of the company’s stock worth $97,575,000 after buying an additional 269,008 shares in the last quarter. Strs Ohio raised its position in shares of BioMarin Pharmaceutical by 50.7% in the second quarter. Strs Ohio now owns 491,556 shares of the company’s stock worth $38,243,000 after buying an additional 165,472 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI raised its position in shares of BioMarin Pharmaceutical by 205.1% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 177,243 shares of the company’s stock worth $13,790,000 after buying an additional 119,149 shares in the last quarter. 97.54% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down 1.23% during midday trading on Wednesday, reaching $85.63. 1,465,092 shares of the company’s stock traded hands. BioMarin Pharmaceutical Inc. has a 1-year low of $62.12 and a 1-year high of $107.56. The firm’s market cap is $14.73 billion. The stock’s 50 day moving average price is $86.14 and its 200 day moving average price is $89.66.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, October 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.13. The company had revenue of $279.90 million for the quarter, compared to analyst estimates of $289.70 million. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. The firm’s revenue was up 34.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.60) EPS. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was first published by Financial Market News and is the sole property of of Financial Market News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this report can be viewed at http://www.financial-market-news.com/aperio-group-llc-raises-stake-in-biomarin-pharmaceutical-inc-bmrn/1211053/.

A number of research analysts have recently commented on BMRN shares. Vetr raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $110.24 price objective for the company in a research report on Tuesday, August 2nd. Stifel Nicolaus upped their price objective on shares of BioMarin Pharmaceutical from $107.00 to $113.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Jefferies Group upped their target price on shares of BioMarin Pharmaceutical from $116.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Credit Suisse Group AG set a $111.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 8th. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a research note on Tuesday, August 9th. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $114.35.

In related news, EVP Jeffrey Robert Ajer sold 18,467 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $95.61, for a total transaction of $1,765,629.87. Following the sale, the executive vice president now directly owns 41,342 shares of the company’s stock, valued at approximately $3,952,708.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $95.34, for a total transaction of $13,096,665.12. Following the sale, the chief executive officer now directly owns 421,161 shares in the company, valued at $40,153,489.74. The disclosure for this sale can be found here. Corporate insiders own 2.50% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.